Clinical Trial: Oral CBD Administration Not Associated with Positive Drug Test Results

Baltimore, MD: The administration of 100mgs of oral CBD is not associated with a positive drug test result for cannabis, according to clinical trial data published in the Journal of Analytical Toxicology.

Investigators affiliated with John Hopkins University, School of Medicine, performed urinalysis examinations of six subjects following their use of pure CBD in a capsule formula, CBD-dominant vaporized cannabis, and placebo.

The consumption of pure oral THC was not associated with the presence of carboxy-THC in urine. By contrast, the administration of vaporized cannabis high in CBD (10.5 percent), but also containing trace amounts of THC (0.39 percent) did yield a positive drug test result for cannabis in two subjects.

Authors concluded: “These data indicate that acute dosing of pure CBD will not result in a positive urine drug test using current federal workplace drug testing guidelines. However, CBD products that also contain ∆9-THC may produce positive urine results for ∆9-THC-COOH. Accurate labeling and regulation of ∆9-THC content in CBD/hemp products are needed to prevent unexpected positive drug tests and unintended drug effects.”

Full text of the study, “Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis,” appears in the Journal of Analytical Toxicology. Additional information about CBD pharmacokinetics is available in the NORML fact-sheet.